In an interview on CNBC’s Mad Money, Albert Bourla said Pfizer is poised to launch several new products over the next 18 months. "We are aiming to have industry-leading growth," he added. The company is looking to go into the private market in China in the coming months.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE:
- Pfizer Inc Reported Earnings. Did it Beat Estimates?
- Pfizer Issues Weak 2023 Guidance; Expects Significant Sales Drop
- Pfizer says incremental share repurchases ‘not high priority at this point’
- Pfizer CFO says increasing investments behind launch products and pipeline
- Pfizer expects revenue from COVID-19 products to grow in 2024